Filing Details

Accession Number:
0001209191-12-046401
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-09-21 16:25:57
Reporting Period:
2012-09-19
Filing Date:
2012-09-21
Accepted Time:
2012-09-21 16:25:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1349077 Lisa Kelly C/O Vertex Pharmaceuticals Incorporated
130 Waverly St.
Cambridge MA 02139
Svp, Human Resources No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-09-19 954 $32.16 18,203 No 4 M Direct
Common Stock Acquisiton 2012-09-19 3,093 $33.00 21,296 No 4 M Direct
Common Stock Disposition 2012-09-19 4,047 $57.61 17,249 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2012-09-19 954 $0.00 954 $32.16
Common Stock Employee Stock Option (right to buy) Disposition 2012-09-19 3,093 $0.00 3,093 $33.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2018-07-23 No 4 M Direct
56,907 2019-10-21 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,957 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $57.61 (range $57.05 to $57.94).
  3. Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Fully vested.